1. Home
  2. MUX vs ARVN Comparison

MUX vs ARVN Comparison

Compare MUX & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo McEwen Mining Inc.

MUX

McEwen Mining Inc.

N/A

Current Price

$9.17

Market Cap

733.1M

ML Signal

N/A

Logo Arvinas Inc.

ARVN

Arvinas Inc.

N/A

Current Price

$6.46

Market Cap

600.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MUX
ARVN
Founded
1979
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
733.1M
600.2M
IPO Year
1994
2018

Fundamental Metrics

Financial Performance
Metric
MUX
ARVN
Price
$9.17
$6.46
Analyst Decision
Strong Buy
Buy
Analyst Count
6
15
Target Price
★ $28.40
$14.00
AVG Volume (30 Days)
★ 1.3M
924.3K
Earning Date
11-09-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 58.84
EPS
0.10
★ 0.88
Revenue
$197,553,000.00
★ $262,600,000.00
Revenue This Year
$19.23
$5.67
Revenue Next Year
$34.88
N/A
P/E Ratio
$96.10
★ $7.65
Revenue Growth
★ N/A
N/A
52 Week Low
$9.59
$6.33
52 Week High
$29.70
$14.20

Technical Indicators

Market Signals
Indicator
MUX
ARVN
Relative Strength Index (RSI) 22.06 37.17
Support Level N/A N/A
Resistance Level $20.62 $7.85
Average True Range (ATR) 0.82 0.45
MACD -0.40 -0.01
Stochastic Oscillator 0.34 11.78

Price Performance

Historical Comparison
MUX
ARVN

About MUX McEwen Mining Inc.

McEwen Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. Its Other operations include: Fox Complex, Gold Bar Complex, Project Fenix, and Los Azules. The company generates its revenue from gold and silver production. Its operating segments include Canada, United States, Mexico, MSC and McEwen Copper, of which it derives maximum revenue from USA.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: